

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/29, C07K 14/415, A23G 9/02, A23L 3/36	A1	(11) International Publication Number: WO 98/04699
		(43) International Publication Date: 5 February 1998 (05.02.98)

(21) International Application Number: PCT/EP97/03634

(22) International Filing Date: 4 July 1997 (04.07.97)

(30) Priority Data:

96305497.8 26 July 1996 (26.07.96) EP

(34) Countries for which the regional or
international application was filed: GB et al.(71) Applicant (for all designated States except AU BB CA GB IE
KE LK LS MN MW NZ SD SG SZ TT UG): UNILEVER
N.V. [NL/NL]; Weena 455, NL-3013 AL Rotterdam (NL).(71) Applicant (for AU BB CA GB IE KE LK LS MN MW NZ SD
SG SZ TT UG only): UNILEVER PLC [GB/GB]; Unilever
House, Blackfriars, London EC4P 4BQ (GB).(72) Inventors: LILLFORD, Peter, John; Unilever Research Col-
worth Lab., Unilever House, Sharnbrook MK44 1LQ (GB).
McARTHUR, Andrew, John; Unilever Research Colworth
Lab., Unilever House, Sharnbrook MK44 1LQ (GB). SIDE-
BOTTOM, Christopher, Michael; Unilever Research Col-
worth Lab., Unilever House, Sharnbrook MK44 1LQ (GB).(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR,
BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE,
GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,
TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE,
LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,
SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML,
MR, NE, SN, TD, TG).**Published**

With international search report.

(54) Title: FROZEN FOOD PRODUCT CONTAINING HEAT STABLE ANTIFREEZE PROTEIN

(57) Abstract

A process for the recovery of AFPs from natural sources, said process involving the steps of a) isolating an AFP containing juice from the natural source; b) heat treating the natural source or the AFP containing juice to a temperature of at least 60 °C; c) removing the insoluble fraction.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

FROZEN FOOD PRODUCT CONTAINING HEAT STABLE ANTIFREEZE PROTEIN

5 Technical Field of the Invention

The invention relates to a process for the isolation of anti-freeze proteins (AFPs) and frozen food product containing AFPs.

10

Background to the Invention

Anti-freeze proteins (AFPs) have been suggested for improving the freezing tolerance of foodstuffs.

15

For the purpose of the invention, the term AFP has the meaning as well-known in the art, namely those proteins which exhibit the activity of inhibit the growth of ice crystals. See for example US 5,118,792.

20

WO 90/13571 discloses antifreeze peptides produced chemically or by recombinant DNA techniques. The AFPS can suitably be used in food-products. Example 3B shows modified ice crystal shapes if a water-ice mixture is
25 frozen into a film in combination with 0.01 wt% of AFP.

WO 92/22581 discloses AFPS from plants which can be used for controlling ice crystal shape in ice-cream. This document also describes a process for extracting a
30 polypeptide composition from extracellular spaces of plants by infiltrating leaves with an extraction medium without rupturing the plants.

WO 94/03617 discloses the production of AFPS from yeast and
35 their possible use in ice-cream. WO 96/11586 describes fish AFPS produced by microbes.

Several literature places also mention the isolation and/or use of plant proteins for cryoprotection. Cryoprotective proteins have a function in the protection of plant membranes against frost damage. These proteins, however, do not possess recrystallisation inhibition properties and are, therefore, not embraced within the terms AFPs.

Hincha in Journal of Plant Physiology, 1992, 140, 236-240 describes the isolation of cryoprotective proteins from cabbage.

Volger in Biochimica et Biophysica Acta, 412 (1975), 335-349 describes the isolation of cryoprotective leaf proteins from spinach.

Boothe in Plant Physiol (1995), 108: 759-803 describes the isolation of proteins from Brassica napus. Again, these proteins are believed to be cryoprotective proteins rather than AFPs.

Neven in Plant Molecular Biology 21: 291-305, 1993 describes the DNA characterisation of a spinach cryoprotective protein.

Salzman in Abstracts and Reviews of the 18th Annual Meeting of the ASEV/Eastern Section in Am. J. Enol. Vitic., Vol. 44, No. 4, 1993 describes the presence of boiling-stable polypeptides in buds of Vitis. Although the proteins are analogous to fish antifreeze peptides, they are cryoprotective proteins and not AFPs.

Lin in Biochemical and Biophysical Research Communication, Vol. 183, No. 3, 1992, pages 1103-1108 and in Lin, Plant Physiology (1992) 99, 519-525 describes the 15 kDa cryoprotective polypeptide from Arabidopsis Hakaira.

Houde in The Plant Journal (1995) 8(4), 583-593 mentions

cryoprotective proteins from wheat.

Furthermore -as illustrated in example VIII- extracts of cabbage, spinach, Brassica napus and Arabidopsis do not
5 have recrystallisation inhibition proteins after heating.

Up till now, however the use of AFPs has not been applied to commercially available food products. One reason for this are the high costs and complicated process for
10 obtaining AFPs. Another reason is that the AFPs which until now have been suggested for use in frozen food products cannot be incorporated in the standard formulation mix, because they tend to destabilise during processing especially during the pasteurisation step. This
15 destabilisation is believed to be caused by the denaturation of the AFPs; this is a well-known effect commonly observed for peptides and proteins.

The present invention aims at providing solutions to these
20 problems.

Surprisingly it has been found that AFPs can be isolated from natural sources such as cold-acclimatised plants by means of a new relatively simple process. This process
25 leads for the first time to the identification of AFPs which can conveniently be incorporated in a mix for the preparation of frozen products before the pasteurisation thereof.

30 Accordingly in a first aspect, the invention relates to a process for the recovery of AFPs from natural sources, said process involving the steps of

- a) isolating a AFP containing juice from the natural source;
- 35 b) heat treating the natural source or the AFP containing juice to a temperature of at least 60°C;
- c) removing the insoluble fraction.

Step c of the above process will usually take place after steps a and b. Step a and b can be done in any desired order, for example step a followed by step b (in that case the AFP rich juice will be heated) or step b followed by
5 step a (in that case the natural source will be heated) or step a and b simultaneously.

Surprisingly we have found that the isolation process of the invention has a number of advantages.

10

Firstly by using the process it is no longer necessary to avoid rupturing of the natural source such as plants such as required in the processes according to WO 92/22581. This immediately significantly increases the commercial
15 applicability of the process, for example as compared to WO 92/22581, because high investment costs for specific processing are no longer necessary.

Also by using the high temperatures it seems possible to
20 extract from a large group of peptides present in the natural sources a new selection of very active AFPs from the natural material, said AFPs including peptides which are very active w.r.t. ice-recrystallisation inhibition properties.

25

Thirdly, contrary to expectations, the use of high temperatures does not denature all the proteinaceous material, but does only seem to denature some of the proteins, while the remaining AFPs have an increased
30 temperature stability. This renders it possible to include the isolated AFPs in compositions which need to be subjected to higher temperatures e.g. a pasteurisation step. This is especially surprising, because for example the AFPs from WO 92/22581 appear not stable under heating
35 conditions (see example VI).

The process of the invention includes in step b the heating

of the natural source or the AFP rich juice to a temperature of more than 60°C. Preferably the temperature is from 60 to 110 °C, most preferably from 80 to 105°C. The heating step can take place after the isolation of the protein rich juice (step a) or before the isolation of the protein rich juice. Any suitable way to heat the juice can be used, for example conventional or microwave heating, heating optionally with an added extraction medium, steaming etc.

If an extraction medium is used, preferably it is used in small volumes to avoid unnecessary dilution of the AFP fraction. Any suitable extraction medium can be used, although the use of water is especially preferred. If desired, additives may be added to the water prior to using it as an extraction medium. Most preferred, however water substantially free of additives is used.

The process of the invention can be applied to any natural source of heat-stable AFPs. Included in this list are plants, fishes, insects and microorganisms. Both natural occurring species may be used or species which have been obtained through genetic modification. For example microorganisms or plants may be genetically modified to express AFPs and the AFPs may then be isolated in accordance to the present invention. AFPs having at least 80%, more preferred more than 95%, most preferred 100% homology to the AFPs directly obtained from natural sources can thus be obtained. For the purpose of the invention proteins possessing this high level of homology are also embraced within the term AFPs. Also these transformed microorganism or plants capable of expressing genes encoding the AFPs are also embraced within the scope of the invention.

Genetic manipulation techniques may be used to produce the heat stable AFPs described in the invention. An appropriate host cell or organism would be transformed by a gene

construct that encodes the desired heat stable polypeptide. The nucleotide sequence coding for the heat stable polypeptide can be inserted into a suitable expression vector containing the necessary elements for transcription and translation and in a manner that they will be expressed under appropriate conditions (eg in proper orientation and correct reading frame and with appropriate targeting and expression sequences). The methods required to construct these expression vectors are well known to those skilled in the art.

A number of expression systems may be utilised to express the heat stable polypeptide coding sequence. These include, but are not limited to, bacteria, yeast insect cell systems, plant cell culture systems and plants all transformed with the appropriate expression vectors.

A wide variety of plants and plant cell systems can be transformed with the nucleic acid constructs of the polypeptides isolated in the heat stable extract. Preferred embodiments would include, but are not limited to, maize, tomato, tobacco, carrots, strawberries, rape seed and sugar beet.

Preferably the AFP is derived from plants (this means that either the AFP is directly obtained from the plant as natural source or AFPs having a high degree of homology to these AFPs are transgenetically produced in other organisms). Any plant containing heat stable AFPs can be used, preferably however are naturally occurring plants (or their genetic modified versions) which are able to grow under cold conditions such that they contain AFPs. Especially preferred is the use of winter-rye, perennial grasses and sedges. Other suitable plants may for example come from the group of woody plants, winter-cereals etc.

Especially preferably the heat stable AFPs are derived from

Acer saccharoides, Bamboo, Buddleia, Isothecium
myosuroides, Ramalina farinaceae, Usnea subfloridana,
Forsythia, Oxalis, Poa Trivialis, Lolium Perenne, Holcus
Lanatus, Bromus Sterilis, Parodiochloa flabellata,
5 Deschampsia antartica, Carex aquatilis, Colobanthus
quintensis and Agrostis tenuis, Festuca contracta and Poa
annua.

The AFP rich juice can be separated from its source by any
10 convenient process for example pressing, filtering,
homogenising, extraction etc. Preferably the natural source
of AFP such as the plant material is made into small pieces
or into a slurry before the protein rich fraction is
collected, for example by filtering. This maceration can be
15 done by any suitable method, for example in a blender. It
will be well within the ability of the skilled person to
divide the material into such a form that collection of the
protein rich juice can readily take place.

20 After collecting and heating (in the desired order) the
protein fraction the resulting AFP containing sample can
then be treated by any convenient process in order to
remove the insoluble fraction and retain the AFP rich
liquid fraction. The insoluble fraction can be removed e.g.
25 by filtering, precipitation etc. The AFP rich liquid can
then advantageously be further processed to concentrate or
isolate the AFPs to bring them in a form suitable for
further use. Examples of suitable processes are drying to
obtain a powder or paste, further concentration to obtain
30 an AFP concentrate, chromatography to separate the AFPs
from the extraction medium etc. Again it will be well
within the ability of the skilled person to determine the
suitable means and conditions for appropriate isolation.

35 For some natural sources the AFPs obtained by the above
methods may consist of a mixture of two or more different
AFP. If desired these AFPs can be separated by any

conventional process for example chromatography or other processes based on the differences in physical/chemical properties such as molecular weight.

- 5 Also if desired the amino acid composition and sequence of the isolated AFPs can be determined. Any suitable method for determining these can be used. Examples of suitable methods are described in the examples. Also if desired the nucleic acid sequence that encodes the AFPs can be
10 determined. Vector containing a nucleic acid sequence capable of encoding the amino acids are also embraced within the scope of the invention.

- Based on the above information it is also possible to
15 genetically modify other natural sources such that they produce the advantageous AFPs as identified here-above. Examples of suitable AFPs are described in the examples.

- 20 It has been found that the AFPs obtained by the above process have an increased ability to withstand thermal treatment. It is believed that such AFPs have never before been isolated. As described above this increased thermal resistance is particularly of interest for use in food-
25 products which undergo a heating step, for example pasteurisation.

- Accordingly another aspect of the invention relates to AFPs which have a thermal stability as evidenced by no
30 significant reduction in the recrystallisation inhibition properties after heat-treatment for one hour at 80°C or 10 minutes at 100°C. A suitable test for determining the ice recrystallisation inhibition properties is described in the examples and involves the quick freezing to -40°C followed
35 by storage for one hour at -60°C. Preferably AFPs which are subject to this test after heat-treatment result in an ice crystal particle size which is less than 5 µm larger than

the ice crystal size of a sample with the same AFP which was not heat-treated. Preferably the difference is less than 3 μm , most preferred less than 1 μm .

- 5 Preferably those AFPs are chosen which have significant ice-recrystallisation inhibition properties. A suitable test for determining the recrystallisation inhibition properties is indicated in the example VI. Preferably AFPs in accordance to the invention provide a ice particle size
10 following an ice recrystallisation inhibition assay -as described in the examples- of 15 μm or less, more preferred from 5 to 15 μm .

The AFPs can conveniently be used in food products,
15 preferably in food products which are frozen or intended to be frozen. Especially preferred is the use of AFPs in products which are heated e.g. by pasteurisation or sterilisation prior to freezing. Especially preferred is the use in frozen confectionery products.

20 Examples of such food products are: frozen confectionery mixes such as ice-cream mixes and water-ice mixes which are intended to be pasteurised prior to freezing. Such mixes are usually stored at ambient temperature. Suitable product
25 forms are for example: a powder mix which is packed for example in a bag or in sachets. Said mix being capable of forming the basis of the frozen food product e.g. after addition of water and optionally other ingredients and - optional- aeration.

30 Another example of a suitable mix could be a liquid mix (optionally aerated) which, if necessary after addition of further components and optional further aeration can be frozen.

35

The clear advantage of the above mentioned mixes is that the presence of the AFP ingredient makes that the mixes can

be frozen under quiescent conditions, for example in a shop or home freezer without the formation of unacceptable ice crystal shapes and hence with a texture different to products normally obtained via quiescent freezing.

5

Very conveniently these mixes are packed in closed containers (e.g. cartons, bags, boxes, plastic containers etc). For single portions the pack size will generally be from 10 to 1000 g. For multiple portions pack sizes of up to 500 kg may be suitable. Generally the pack size will be from 10 g to 5000 g.

As indicated above the preferred products wherein the AFPs are used are frozen confectionery product such as ice-cream or water-ice. Preferably the level of AFPs is from 0.0001 to 0.5 wt% based on the final product. If dry-mixes or concentrates are used, the concentration may be higher in order to ensure that the level in the final frozen product is within the above ranges.

20

Surprisingly it has been found that compositions of the invention can contain very low amounts of AFPs while still being of good quality.

Surprisingly it has been found that the level of AFPs can be as low as 0.1 to 50 ppm while still providing adequate recrystallisation properties and temperature tolerance in frozen confectionery products. Although applicants do by no means wish to be bound by any theory, the reason for this may be that the interaction between the solids of the frozen confectionery and the AFPs provides an excellent mechanism for inhibiting crystal growth. Most conveniently the level of AFP is from 1 to 40 ppm, especially preferred from 2 to 10 ppm.

35

For the purpose of the invention the term frozen confectionery product includes milk containing frozen

confections such as ice-cream, frozen yoghurt, sherbet, sorbet, ice milk and frozen custard, water-ices, granitas and frozen fruit purees. For some applications the use in fermented food products is less preferred.

5

Preferably a the level of solids in the frozen confection (e.g. sugar, fat, flavouring etc) is more than 4 wt%, for example more than 30 wt%, more preferred from 40 to 70wt%.

- 10 Frozen confectionery products according to the invention can be produced by any method suitable for the production of frozen confectionery. Especially preferably however all the ingredients of the formulation are fully mixed before pasteurisation and before the freezing process starts. The
- 15 freezing process may advantageously involve a hardening step, for example to a temperature of -30 Fahrenheit or lower.

20

Example I

Isolation of AFPs by first collecting the juice followed by heat treatment and isolation of the AFP.

5

Winter rye (Halo variety) was cut in January (mean temperature in that month was 3.5 °C ensuring the appropriate cold acclimatization of the plants). The tissue was rapidly transported into the laboratory for further handling and washed thoroughly with water to remove dirt.

400 g of the clippings were homogenised at ambient temperature in a Waring blender with 800 g water until the leaf tissue was completely disrupted. The AFP rich juice was collected by filtering through 4 layers of muslin.

The AFP rich juice was then subjected to a temperature treatment by boiling the juice for 10 minutes. This caused the precipitation of protein while the AFP for use in accordance to the invention remained in solution. The supernatant was separated from the precipitate by centrifuging at 15,000 g for 20 minutes or by further filtration through muslin.

25

The AFPs can be isolated from the supernatant by freeze drying.

For control purposes an apoplastic extract (extracellular extract) of winter rye can be obtained as follows: The leaves from 30 days cold acclimated rye plants were cut into 3 cm lengths and thoroughly washed in distilled water to remove any cell contents. The leaf pieces were patted dry on paper towel and totally immersed in an extraction medium of 5 mM EDTA, 10 mM ascorbic acid, 2 mM caproic acid, 2 mM benzamidine and 1 mM Phenylmethylsulphonyl Fluoride (PMSF). They were then vacuum infiltrated in a

Buchner flask for 60 minutes after which time the leaves were removed and patted completely dry. They were then arranged lengthways in a cut off plastic syringe barrel and centrifuged gently at 2000 X g for 30 minutes. The
5 apoplastic extract was collected in an eppendorf tube below the syringe.

Example II

Isolation of AFPs by first heating the natural source,
followed by isolating the AFP rich juice and isolation of
5 the AFP.

Mixed grass tissue (Poa Trivialis, Lolium Perenne, Holcus
Lanatus, Bromus Sterilis) was cut in January (mean
temperature in that month was 3.5 °C ensuring the
10 appropriate cold acclimatization of the plants). The grass
tissue was rapidly transported into the laboratory for
further handling and washed thoroughly with water to remove
dirt.

15 500 g of grass clippings was placed in a 650 Watt microwave
oven and heated at full power for 5 minutes, whereby the
temperature was raised to 85 to 100°C. The grass clippings
were then cooled to ambient temperature.

20 Alternatively the grass clippings are mixed with 500 g
boiling water and the mixture is re-heated to 100 °C
followed by boiling for 10 minutes under stirring and then
allowed to cool to 60 °C.

25 After the heating step the AFP rich juice was separated
from the clippings by filtering. The mass was stirred
continuously for 5 minutes in the presence of an equal
volume of water and then squeezed through 3 layers of
muslin.

30

The supernatant can be freeze dried to remove the water
followed by storage. Alternatively the supernatant can be
frozen for storage.

35

Example III

A liquid pre-mix for preparing ice-cream was made by mixing:

5		
	Ingredient	% by weight
	Skimmed milk powder	11.390
	Sucrose	3.410
	Maltodextrine (MD40)	4.000
10	Locust bean gum	0.072
	Corn Syrup 63DE	20.705
	Guar Gum	0.048
	Genulacta L100	0.020
	Butter	9.015
15	Avicel RC581	0.240
	Gelatin	0.140
	Monoglyceride (palmitate)	0.450
	Vanillin	0.010
	AFP (of example I*)	0.100 or none (control)
20	Water	balance

*Note: AFP is added as concentrated AFP solution using some of the added water as a diluent , percentage refers to amount of AFP.

25

This mix can conveniently be pasteurised at 85°C for 15 seconds and stored chilled in a can.

The mixes can be used in the preparation of a ice-cream by
30 whipping with a conventional house-hold mixer to an overrun of about 100%, followed by quiescently freezing into a house-hold freezer. The composition according to the invention had a markedly better texture than the control sample.

35

Very good results are obtained by using the AFP of Example II instead of the AFP of example I.

Example IV

A liquid premix for the preparation of ice-cream was prepared by mixing:

5		
	Ingredient	% by weight
	Skimmed milk powder	10.00
	sucrose	13.00
	maltodextrine (MD40)	4.00
10	Locust bean gum	0.14
	butter oil	8.00
	monoglyceride (palmitate)	0.30
	vanillin	0.01
	AFP (of example I*)	0.01 or none(control)
15	water	balance

*Note: AFP is added as concentrated AFP solution in some of the water, percentage refers to amount of AFP.

20 The ingredients were mixed at ambient temperature followed by pasteurisation for 60 seconds at 89°C. The mix was aseptically filled into packs of 500 ml, sealed and stored at ambient temperatures.

25 The mix can be used for the preparation of ice-cream by whipping it with a conventional house-hold mixer to an overrun of about 70 % followed by freezing under quiescent conditions in a house-hold freezer.

30 After two months storage the composition according to the invention had a markedly better texture than the control sample.

35 Very good results are obtained by using the AFP of Example II instead of the AFP of example I.

Example V

Example IV was repeated, but now the ice-cream mix was pre-aerated to an overrun of 70 % prior to aseptically filling
5 and sealing.

The resulting product can be stored at ambient temperature and an ice-cream can be produced by placing the mix in a house-hold freezer and freezing under quiescent conditions.
10

Example VI

The ice recrystallisation inhibition properties of the AFPs can determined as follows:

5

A sample of an AFP containing product was adjusted to a sucrose level of 30 wt% (If the starting level of the sample was more than 30% this was done by dilution, if the starting level was lower sucrose was added to the 30%

10 level).

A 3 μ L drop of the sample was placed on a 22 mm coverslip. A 16 mm diameter cover-slip was then placed on top and a 200 g weight was placed on the sample to ensure a uniform
15 slide thickness. The edges of the coverslip were sealed with clear nail varnish.

The slide was placed on a Linkham THM 600 temperature controlled microscope stage. the stage was cooled rapidly
20 (50 °C per minute) to -40°C to produce a large population of small crystals. The stage temperature was then raised rapidly (50°C per minute) to -6 °C and held at this temperature.

25 The ice-phase was observed at -6 °C using a Leica Aristoplan microscope. Polarised light conditions in conjunction with a lambda plate were used to enhance the contrast of the ice crystals. The state of the ice phase (size of ice crystals) was recorded by 35 mm
30 photomicrography at T=0 and T=1 hour.

Generally this test can be applied to any suitable composition comprising AFP and water. Generally the level of AFP in such a test composition is not very critical and
35 can for example be from 0.0001 to 0.5 wt%, more preferred 0.0005 to 0.1 wt%, most preferred 0.001 to 0.05 wt%, for example 0.01 wt%

Any suitable composition comprising AFP and water can be used to carry out the test. Generally, however, it will not be necessary to obtain the AFP in purified form. For practical applications normally it would suffice to prepare
5 a liquid extract or juice of natural material, wherein this extract or juice can then be tested.

This method can be applied for example to the AFP containing extracts as obtained in example I or II, with or
10 without a concentration step.

The recrystallisation inhibition properties of several samples was measured. The samples were obtained from rye which were harvested at several moments during the year.
15 The AFP juices obtained after extraction and heating in accordance to example I were measured for their recrystallisation properties as above. As a comparison rye was used which was grown in a greenhouse (at temperatures which normally do not induce AFP formation)

20

The following ice crystal sizes were measured

Sample		Ice crystal size after 1 hour (μm)
	Control	25
25	sample December	17
	sample January	10
	sample February	15
	sample March	18
	sample April	18
30	sample May	25

These measurements show that for good AFP activity the plants should be harvested during the winter months e.g. December-April. Especially preferred are samples capable of
35 providing ice crystal sizes of 15 μm or less. In this case this can be achieved by harvesting the plants in January or February.

The same measurements were done on the AFP samples of January which were heat treated (1 hour at 60 °C). No significant reduction in recrystallisation properties was observed.

5

As a comparison the apoplastic extract of example I was used. This resulted in a final ice crystal size after 1 hour of 11.1 µm; after heat treatment by boiling for 10 minutes at 100 °C the test resulted after 1 hour in a ice
10 crystal size of 16.8 µm. This example shows that the apoplastic extract from winter rye is not heat stable.

Example VII

- Non heat treated grass extract from grass harvested in
 5 January was obtained from Silsoe (UK). The extract was
 centrifuged for 1 hour to remove soil and insoluble debris
 as follows, Centrifuge: Sorvall RC3C, Rotor
 :H6000A, Temperature: +5°C, Rotor Speed: 5000rpm (7268g).
- 10 A sample of the extract was freeze dried to determine its
 total solids content. This was found to be 11.48 mg/ml. The
 dried extract was then rehydrated with 30% Sucrose solution
 to its original total solids concentration. Several
 solutions were prepared by diluting the extract as
 15 necessary with 30% Sucrose solution.
- Antifreeze activity was measured using the assay of example
 VI.
- 20 The T=0 and T=1 hour pictures from the recrystallisation
 inhibition assays had their mean ice crystal sizes measured
 using the Zeiss TGA 10 analyser. The results obtained are
 shown in the table below.

Sample	Total Solids (mg/ml)	Ice Crystal Size (µm)		Ice Crystal Growth in 1 hour at -6°C (µm)
		T=0	T=1 hour at -6°C	
Undiluted	11.48	5.2	7.3	2.1
50% Extract	5.74	5.5	7.6	2.1
25% Extract	2.87	6.3	8.9	2.6
12.5% Extract	1.435	6.6	13.1	6.5
6.25% Extract	0.7175	8.1	14.7	6.6

3.125% Extract	0.359	7.4	17.0	9.6
1.5625% Extract	0.179	9.0	20.3	11.3

5
These results show the variation in final crystal size and the change in ice crystal size over 1 hour at -6°C for the various dilutions of grass extract. It can be seen that the solids level in the grass extract can be varied in a wide
10 range while still good recrystallisation inhibition properties are obtained. Preferably those concentrations are chosen which result in an ice crystal size after 1 hour of 15 micrometer or less.

15 A similar test was done with grass extract which had been subjected to heat treatment (10 minutes at 100 °C). No significant deterioration of recrystallisation inhibition properties was seen.

20 Additionally the grass extracts of example II were tested using the same recrystallisation inhibition test. The following results were obtained:

Heat 25 treatment	Crystal Size in μm	
	T=0	T=1
60 °C 1 hour	9.6	11.1
Boil 10 minutes	9.8	11.3

30 These results show that even after heating the extract of cold acclimatised grass maintained the ability to inhibit ice crystal growth.

Example VIII

Several AFP containing plants were harvested in January.
5 Extracts were obtained by grounding fresh tissue, for
example roots, stems, buds or leaves with a pestle and
mortar (cooled to 4 °C) in a equal volume of buffer A (10
mM EDTA, 20 mM Ascorbic acid, buffered with Tris to pH 7.4)
held on ice. The homogenates are filtered through one or
10 more layers of muslin and kept on ice prior to further
used.

The extracts were subjected to the recrystallisation
inhibition test of example VI both after heating for 60 C
15 for 1 hour and boiling for 10 minutes.

The following plants contained heat stable AFPs as
evidenced by the maintenance of recrystallisation
inhibition properties: *Acer saccharoides*, *Bamboo*, *Buddleia*,
20 *Isothecium myosuroides*, *Ramalina farinaceae*, *Usnea*
subfloridana, *Forsythia*, *Oxalis*, *Poa Trivialis*, *Lolium*
Perenne, *Holcus Lanatus*, *Bromus Sterilis*, *Parodiochloa*
flabellata, *Deschampsia antartica*, *Carex aquatilis*,
Colobanthus quintensis and *Agrostis tenuis*, *Festuca*
25 *contracta* and *Poa annua*.

The following plants did not contain heat stable AFPs:
cabbage, spinach, *Brassica napus* and *Arabinopsis*.

Example IX

The thermal hysteresis activity of the AFPs can be tested
5 as follows:

1 ml samples were placed in Eppendorfs in a hot water bath
and heated for 1 hour at 60 °C. The thermal hysteresis
properties of the sample were then measured as follows:

10

The melted product is placed on a microslide (Camlab
Cambridge, path length 0.1 mm). The ends of the microslide
are sealed with petroleum jelly.

15 Ice is introduced into the sample using an aerosol freezing
spray. The slide was then immersed in ethanol temperature
regulated bath at -0.1 °C. After 5 minute equilibration the
sample is checked. if the ice melts completely the
temperature of the bath was lowered in 0.1°C steps followed
20 by equilibration. These steps are repeated until a
temperature was reached where a small amount of ice
crystals exist in the sample. After equilibration at that
temperature, the bath temperature was decreased in steps of
0.01 °C per minute. The freezing point of the sample is
25 recorded as the temperature at which the ice propagation
begins from the equilibrated crystals.

The melting temperature of the sample is then determined by
raising the temperature starting at the freezing point in
30 steps of 0.01 °C per minute until all ice crystals melt.
This temperature is the melting temperature of the sample.

The thermal hysteresis of the sample is the difference
between the melting temperature and the freezing
35 temperature.

This test procedure is done on a first sample (prior to

heat treatment) and on a second sample after heat treatment, followed by cooling.

Similarly the heat stability can be determined by the above
5 test wherein the sample is boiled in water for 30 seconds followed by determining the thermal hysteresis. The thermal hysteresis of several samples was measured.

The samples were obtained from winter-rye which were
10 harvested at several moments during the year. The AFP juices obtained after extraction and heating in accordance to example I were measured for their thermal hysteresis as in example VI. As a comparison winter-rye was used which was grown in a greenhouse (at temperatures which normally
15 do not induce AFP formation)

The following thermal hysteresis was measured

	Sample	Thermal hysteresis (°C)
20	Control	0.04
	sample December	0.18
	sample January	0.21
	sample February	0.17
	sample March	0.15
25	sample April	0.12
	sample May	0.05

These measurements show that for good AFP activity the plants should be harvested during the winter months e.g.
30 December-March.

The same measurements were done on the AFP samples of January which were heat treated (1 hour at 60°C) No significant reduction in thermal hysteresis was observed.

Example X

Determination of amino acid sequence of AFPs

5

The heat stable grass extract of example II was concentrated approximately ten times using an Amicon ultrafiltration chamber with 10kDa cut-off membrane. The resulting concentrate was loaded onto a Mono Q (Pharmacia) 10 HR 5/5 FPLC anion exchange column. Binding to the column was in 50mM Tris/HCl buffer pH 8.5 and the RI active fraction was eluted with a linear gradient of NaCl to a final concentration of 0.5M in the same pH 8.5 Tris buffer. Chromatography was carried out at a flow rate of 1ml min⁻¹ 15 and 1 ml fractions were collected and assayed for recrystallisation inhibition activity (as in example IX).

The active fractions were pooled together and concentrated to a volume of 0.05 ml on a centricon PM10 centrifugal 20 concentrator (Amicon) centrifuged at 10,000rpm for 10 minutes in a Sorvall SS 34 rotor (8 x 50 ml). The concentrate was loaded onto a Superdex 75 PC 3.2/30 gel filtration column running on a SMART microseparation system (Pharmacia). The column was eluted with 50mM Tris/HCl 25 buffer pH 8.5 at a flow rate of 0.05 ml min⁻¹. Fractions of 0.05 ml were collected after the sample was loaded to a total volume of 3.5 ml. Fractions were assayed for recrystallisation inhibition activity (as in example IX) and the most active fractions were subjected to separation 30 on an SDS PAGE gel and electroblotting prior to N-terminal sequencing.

The active Superdex 75 fractions were taken up in gel loading buffer (50mM Tris/HCl, pH 6.8, 10% glycerol, 10mM 35 dithiothreitol, 2% SDS) and then separated on a 10% polyacrylamide gel following the Laemmli method. After electrophoresis the gel was sandwiched against a sheet of

methanol wetted Problott (Perkin Elmer) membrane and electroblotted at 20 volts for 16 hours in 10mM 3(cyclo-hexylamino) - 1 - propane sulphonic acid (CAPS) buffer (pH 11.0) containing 10% methanol. After blotting, the membrane
5 was washed briefly with methanol and then milli Q (Millipore) water and the bound proteins visualised with a solution of 0.1 % (w/v) coomassie brilliant blue.

Two protein bands of apparent molecular weights 25kDa and
10 35kDa were visualised by the coomassie staining. The 35 kDa protein appeared to particularly closely correlate to the most RI active fractions. Both of these bands were excised with a scalpel blade and sequenced. An unstained area of the membrane corresponding to an apparent molecular weight
15 of 65 - 75 kDa was also subjected to sequencing as silver staining of gels of the most active fractions had previously shown a protein band at this molecular weight.

All three excised areas of membrane were sequenced by
20 loading into a Blott sequencing cartridge and the sequence determined using reaction and conversion cycles as described by the manufacturer (Perkin-Elmer). N-terminal sequence-listings are given below.

25 The 25 kDa AFP comprises a sequence from the N terminus substantially homologous to:-
ALA-THR-ILE-THR-ALA-VAL-ALA-VAL-LEU-LYS-X-THR-VAL-GLU-VAL-
X-ILE-VAL-PRO-THR

30 The 35 kDa AFP comprises a sequence from the N terminus substantially homologous to:-
ALA-GLN-PHE-THR-ILE-THR-ASN-LYS-CYS-GLN-PHE-THR-VAL-TRP-
ALA-ALA-X-VAL-PRO

The 65-70 kDa AFP comprises a sequence from the N terminus substantially homologous to:-

X-GLU-GLN-PRO-ASN-THR-ILE-X-GLY-THR

- 5 In each sequence X denotes an unknown which may be any amino acid found in plant proteins. For the purpose of the invention the term substantially homologous refers to at least 80 % overlap in amino acids, more preferred more than 90%, most preferred 95 to 100%.

Claims

1. A process for the recovery of AFPs from natural sources, said process involving the steps of
 - a) isolating an AFP containing juice from the natural source;
 - b) heat treating the natural source or the AFP containing juice to a temperature of at least 60°C;
 - c) removing the insoluble fraction.
2. A process in accordance to claim 1, wherein steps a and b (in either order) take place before step c.
3. AFPs having a thermal stability as evidenced by no significant reduction in ice recrystallisation inhibition properties after heat-treatment for 1 hour at 60 °C, one hour at 80 °C or 10 minutes at 100 °C.
4. AFPs according to claim 3 wherein the ice crystal size of a composition of heat-treated AFP in water after quick freezing to -40 °C followed by storage at -6 °C for 1 hour is less than 5 µm larger than the ice crystal size of the same AFP which is not heat-treated.
5. AFPs according to claim 3 or 4, wherein the ice crystal size of a composition of the AFP in water after quick freezing to -40 °C followed by storage at -6 °C for 1 hour is 15 µm or less.
6. AFPs according to claim 3 or 4 comprising one or more proteins having a molecular weight of 25 kDa, 35 kDa and 65-75 kDa.

7. AFPs according to claim 6 having a N-terminal sequence from the substantially homologous to:

25 kDa AFP:
ALA-THR-ILE-THR-ALA-VAL-ALA-VAL-LEU-LYS-X-THR-VAL-GLU-VAL-X-ILE-VAL-PRO-THR

35 kDa AFP:
ALA-GLN-PHE-THR-ILE-THR-ASN-LYS-CYS-GLN-PHE-THR-VAL-TRP-ALA-ALA-X-VAL-PRO

65-75 kDa AFP:
X-GLU-GLN-PRO-ASN-THR-ILE-X-GLY-THR
8. Vector containing a nucleic acid sequence capable of encoding at least one of the AFPs of claim 7.
9. Transformed organism capable of expressing at least one of the AFPs of claim 7.
10. Frozen confectionery product comprising from 0.0001 to 0.5 wt% of the AFP according to claim 3.
11. Pre-mix suitable for use in the production of a frozen confectionery product according to claim 10, comprising the AFP of claim 3.
12. Process for the preparation of a frozen confectionery product comprising the preparation of a formulation mix comprising 0.0001 to 0.5 wt% of an AFP, said AFP having a thermal stability as evidenced by no significant reduction in ice recrystallisation inhibition properties after heat-treatment for 1 hour at 60 °C, one hour at 80 °C or 10 minutes at 100 °C, followed by freezing the mix under quiescent conditions.

INTERNATIONAL SEARCH REPORT

Intern. Application No.

PCT/EP 97/03634

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/29 C07K14/415 A23G9/02 A23L3/36

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K A23G

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HINCHA DK ET AL: "CRYOPROTECTIVE LEAF PROTEINS - ASSAY-METHODS AND HEAT-STABILITY" JOURNAL OF PLANT PHYSIOLOGY, 1992, 140, 236-240, XP000614564 see abstract	1-3
Y	see page 239, left-hand column, paragraph 3; figure 3	8-12
X	--- VOLGER H G ET AL: "CRYOPROTECTIVE LEAF PROTEINS" BIOCHIMICA ET BIOPHYSICA ACTA, 412 (2). 1975 335-349., XP000616065 see abstract see page 341, paragraph 5 - page 342, paragraph 1 --- -/--	3

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

24 September 1997

Date of mailing of the international search report

06.10.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Gurdjian, D

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internal Application No

PCT/EP 97/03634

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9222581 A	23-12-92	AU 1907192 A	12-01-93
		CA 2110510 A	23-12-92
		EP 0589928 A	06-04-94

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 92 22581 A (UNIV WATERLOO) 23 December 1992 see claims 1-26 ---	10-12
Y	LIN, C.: "A cold-regulated Arabidopsis gene encodes a polypeptide having potent cryoprotective activity" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS., XP002027263 see the whole document ---	8,9
A	BOOTHE JG ET AL: "EXPRESSION OF A LOW-TEMPERATURE-INDUCED PROTEIN IN BRASSICA-NAPUS" PLANT PHYSIOLOGY, 1995, 108, 795-803, XP002027264 see the whole document ---	1-3
X	NEVEN L G ET AL: "CHARACTERIZATION OF A SPINACH GENE RESPONSIVE TO LOW TEMPERATURE AND WATER STRESS" PLANT MOL BIOL, 21 (2). 1993. 291-305., XP002027265 see page 293, right-hand column, paragraph 3 ---	3
X	SALZMAN R ET AL: "Cold acclimated buds of Vitis spp. express boiling-stable polypeptides analogous to fish antifreeze proteins" 18TH ANNUAL MEETING OF THE ASEV (AMERICAN SOCIETY FOR ENOLOGY AND VITICULTURE)/EASTERN SECTION, ROCHESTER, NEW YORK, USA, JULY 1993. AMERICAN JOURNAL OF ENOLOGY AND VITICULTURE, 44 (4). 1993. 468., XP002027266 see abstract ---	3
X	HOUDE M ET AL: "Immunolocalization of freezing-tolerance-associated proteins in the cytoplasm and nucleoplasm of wheat crown tissue" PLANT JOURNAL, 8 (4). 1995. 583-593., XP002027267 see abstract ---	3
X	LIN C ET AL: "DNA SEQUENCE ANALYSIS OF A COMPLEMENTARY DNA FOR COLD-REGULATED ARABIDOPSIS GENE COR15 AND CHARACTERIZATION OF THE COR 15 POLYPEPTIDE" PLANT PHYSIOL (BETHESDA), 99 (2). 1992. 519-525., XP002027268 see abstract -----	3

Form PCT/ISA/210 (continuation of second sheet) (July 1992)